Filing Flows › Industrials › Rapid Micro Biosystems (RPID)
Rapid Micro Biosystems (RPID) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 7, 2026 · Rapid Micro Biosystems (RPID) Q2 2026 earnings results →
Q2 2026 Revenue up 11% year over year to $8.1M · 160¢ of every $1 of revenue lost · operating margin -153.0%
Rapid Micro Biosystems made $8.1M in Q2 2026 (+11% Y/Y): Product $5.3M, Service $2.8M. Operating margin -153.0%, net loss $12.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 7, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $8.1M in Q2 2026, up 11% year over year and up 1% from the previous quarter. Product was the largest line at 66% of revenue. Product added $484K year over year (up 10%), 61% of the total change.
Gross margin was 15.0%, up 11.3 points from Q2 2025. Operating costs exceeded revenue by $12.3M, an operating margin of -153.0%. Operating expenses grew 9% against revenue growth of 11%. The fastest-growing cost line was General & admin (+11%). The quarter ended with a net loss of $12.9M, narrower than the previous quarter's $14.3M loss.
Operating cash flow was −$12.7M. Non-cash charges added back $674K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $1.8M. Capital expenditures of −$223K exceeded it, leaving free cash flow of −$12.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 7, 2026 | $8.1M | +11% | -153.0% | −$12.9M | −$12.7M |
| Q1 2026 | 10-Q | May 15, 2026 | $8.0M | +11% | -173.1% | −$14.3M | −$15.1M |
| Q4 2025 | 10-K | Mar 12, 2026 | $11.3M | +37% | -108.2% | −$12.5M | −$3.2M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $7.8M | +3% | -145.1% | −$11.5M | −$9.1M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $7.3M | +10% | -167.3% | −$11.9M | −$9.7M |
| Q1 2025 | 10-Q | May 9, 2025 | $7.2M | +28% | -161.8% | −$11.3M | −$9.1M |
| Q4 2024 | 10-K | Feb 28, 2025 | $8.2M | +30% | -124.5% | −$9.7M | −$9.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Rapid Micro Biosystems
We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing. We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics and cell and gene therapies, vaccines, and sterile injectables.
In its own words, from its 10-K, filed Mar 12, 2026.
Rapid Micro Biosystems against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +11% against the peers' median +5%. Operating margin: -153.0% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RPID Rapid Micro Biosystems | Q2 2026 | $8.1M | +11% | -153.0% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: Rapid Micro Biosystems 10-Q on SEC EDGAR · CIK 1380106 · Laboratory Analytical Instruments
13F: who owns RPID and who is buying
More on RPID
- How Rapid Micro Biosystems makes money: revenue by segment
- Rapid Micro Biosystems next earnings date and what analysts expect
- Rapid Micro Biosystems stock forecast, price target and fair value
- Who owns Rapid Micro Biosystems stock: holders, funds and Congress trades
- Rapid Micro Biosystems recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results